This course is part of the Strategies for Effective Pain Management in Clinical Practice curriculum.
Virtual CME Program
3.50 CME/CE Credit
Strategies for Effective Pain Management in Clinical Practice
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including nonopioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
3.50 AMA PRA Category 1 Credits, 3.50 ABIM MOC or 3.50 AANP, including 2.06 AANP Pharm
Release Date: 12/15/2022
Expiration Date: 10/31/2023
- Discuss all options for pain management, including non-pharmacologic and pharmacologic approaches
- Explain the definitions and mechanisms of pain
- Identify the appropriate pain assessment and assessment of potential risk factors for abuse and opioid use disorder/addiction
- Develop individualized treatment plans which appropriately integrate opioids to meet the needs of patients
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, as well as safe storage and disposal
- Summarize counseling strategies, including counseling about the use of naloxone for opioid overdose
- Recognize opioid use disorder and act appropriately to treat or refer those patients
Charles E. Argoff, MD, FABPM
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Katherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD, FABPM: Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel, Kowa Pharmaceuticals America, Lilly, Lundbeck, Neumentum, Nevro, Redhill Biopharma, and Teva Pharmaceuticals. Advisory Board: AbbVie, Amgen, Averitas Pharma, BioDelivery Sciences International, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Regeneron, SK Life Sciences, Tremeau Pharmaceuticals, Teva, Tris, Vertex and Xgene Pharma. Consulting: EnZen Therapeutics, Neumentum, Opioid PMR Consortium, PainScripts, and Xgene Pharmaceutical. Researcher: AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Royalties or patent beneficiaries: Elsevier. Stock Holder: Pfizer and Trevena. Other services provided: Collegium.
Oscar A. de Leon-Casasola, MD: Advisory board: Esteve Pharmaceuticals, Heron Therapeutics and Tremeau Pharmaceuticals. Consultant: Kowa Pharmaceuticals.
Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships have been disclosed.
Charles Vega, MD (Moderator): Consultant: Johnson & Johnson.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 3.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 3.50 contact hour of continuing education, which includes 2.06 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity (“Strategies for Effective Pain Management in Clinical Practice” sessions), which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory (https://www.continuingcertification.org), Strategies for Effective Pain Management in Clinical Practice has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
ABMS Lifelong Learning CME Activity:
Allergy and Immunology
Colon and Rectal Surgery
Physical Medicine and Rehabilitation
Psychiatry and Neurology
This MOC/CME is self-reported to the Boards listed above.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
For guidance on how clinicians can attest to participation in a MIPS Improvement Activity, visit https://qpp.cms.gov/mips/improvement-activities
State Licensure Requirements
This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.
Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.
Supporters and Partners
REMS Program Companies
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.